This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThromboGenics Business Update H1 2013

Financial Update

  • Revenues for the six months ended 30 June 2013 amounted to €102.7 million, compared to €75.1 million for the same period in 2012
  • US sales of JETREA ® for the first six months of 2013 amounted to €12.5 million
  • At the end of June 2013, the Company had a cash balance of €193.6 million
  • ThromboGenics reported a net profit of €54.6 million for the first six months of 2013
  • In March, the Company's shares started trading as part of the BEL20 index on the Euronext stock exchange

Commercializing JETREA ® (ocriplasmin)   in the US

  • ThromboGenics launched JETREA ® in the US on 14 January after it was approved as the first and only pharmacological treatment for symptomatic VMA
  • JETREA ® offers for the first time a treatment option for patients suffering from symptomatic VMA
  • Highly focused commercial team, including specialty sales force, working to build the US sales of JETREA ® and to increase awareness of the benefits of treating symptomatic VMA
  • ThromboGenics reimbursement support team in place to aid US physicians gain reimbursement for JETREA ® and assist qualified patients with potential co-pay burdens.
  • Permanent J-code expected January 1, 2014. A permanent J-code will assist in automated claims adjudication that will result in physicians being reimbursed in a more expedient manner
  • Early response from the US retina community suggests JETREA representing game-changing therapeutic approach for patients suffering from symptomatic VMA. True innovation takes time to find its way to the market and requires further medical education to ensure this novel product delivers its full commercial potential
  • JETREA ® US sales at end of June amounted to €12.5 million ( $US 16.6 million)
  • JETREA ® EU sales royalties at end of June amounted to €0.2 million
  • 51% of total targeted retina practices have ordered JETREA ® (vs 40% end of April 2013)
  • 62% of these practices have reordered the product (vs. 50% end of April 2013)
  • To date, the majority of JETREA ® has been used in moderate to severe patients

Commercializing JETREA ® in Europe and ROW

  • In March 2013, the European Medicines Agency (EMA) approved JETREA ® for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns
  • Partner Alcon launched JETREA ® in the UK in March, followed by Germany and the Nordic region
  • ThromboGenics received €90 million in milestone payments from Alcon: €45 million for the EU approval of JETREA ® and a further €45 million for the first sale of the drug in Europe
  • On August 30, 2013, the UK's National Institute of Health and Care Excellence (NICE) will issue its Final Appraisal Determination (FAD) for JETREA ® regarding reimbursement within the National Health Service (NHS) for the treatment of VMT
  • IQWiG, the German body that evaluates a drug's quality and efficiency, has confirmed that JETREA ® demonstrates major/significant added value compared with existing comparative treatment, when treating patients with mild/moderate vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns. Final guidance IQWiG expected in October 2013.
  • JETREA ® receives approval in Canada for the treatment of symptomatic vitreomacular adhesion (VMA)

JETREA ® Phase IIa wet AMD trial

  • ThromboGenics has reported positive data from a Phase IIa study showing that JETREA ® has potential to resolve VMA in patients with wet age-related macular degeneration (wAMD)
  • In the study (n=100 patients), at Day 28, 24% of the treated patients achieved resolution compared to 12% in the sham injection arm (primary endpoint, p=0.26)
  • No unexpected safety issues were identified, and the safety profile is consistent with the previous pivotal trials' safety data
  • Further studies to evaluate these potential clinical benefits are warranted
  • The full study results will be presented at AAO in November 2013

Dr. Patrik De Haes, CEO of ThromboGenics, said: "ThromboGenics has continued to make good progress delivering a number of key corporate milestones during the first half of 2013. The most important being our US commercial organization's launch of JETREA ® , the first pharmacological treatment for the progressive sight-threatening condition symptomatic VMA."

"Since launch we have succeeded in treating approximately 6% of the patients with moderate to severe symptomatic VMA in the  US . We will continue to work to build our share of this established market and at the same time look to gradually increase the use of JETREA ®   in mild to moderate patients, most of whom currently undergo watchful waiting. We believe that JETREA ® offers real value to these patients as it provides them with a new option that could prevent them having to experience a deterioration in their visual acuity and quality of life before being treated."

"Outside the US our partner Alcon has achieved a number of key milestones including introducing JETREA ®   in its first European market in May. It has also received positive health technology assessments in both the UK and Germany that have confirmed the value of JETREA ®   in treating patients with mild to moderate symptoms of VMA/VMT."

"We remain confident that with JETREA ® , we have provided the global retina community with a novel product that in time will play an important role in greatly expanding the number of patients with mild to moderate symptomatic VMA that can be treated pro-actively."

A conference call for analysts, press and investors will be hosted by Dr Patrik De Haes, CEO of ThromboGenics, and Chris Buyse, CFO of ThromboGenics, today at 06:30 PM CET, 12:30 PM EST.

The dial-in numbers and participant passcode for the call are set out below:

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,067.03 +26.66 0.15%
S&P 500 2,116.31 +4.58 0.22%
NASDAQ 5,096.98 +14.0510 0.28%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs